Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Aberrations of TACC1 and TACC3 are associated with ovarian cancer.

BMC women's health

Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD, Still IH.
PMID: 15918899
BMC Womens Health. 2005 May 26;5:8. doi: 10.1186/1472-6874-5-8.

BACKGROUND: Dysregulation of the human Transforming Acidic Coiled Coil (TACC) genes is thought to be important in the development and progression of multiple myeloma, breast and gastric cancer. Recent, large-scale genomic analysis and Serial Analysis of Gene Expression data...

Cite
Lauffart B, Vaughan MM, Eddy R, et al. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health. 2005;5:8doi: 10.1186/1472-6874-5-8.
Lauffart, B., Vaughan, M. M., Eddy, R., Chervinsky, D., DiCioccio, R. A., Black, J. D., & Still, I. H. (2005). Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC women's health, 58. https://doi.org/10.1186/1472-6874-5-8
Lauffart, Brenda, et al. "Aberrations of TACC1 and TACC3 are associated with ovarian cancer." BMC women's health vol. 5 (2005): 8. doi: https://doi.org/10.1186/1472-6874-5-8
Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, Black JD, Still IH. Aberrations of TACC1 and TACC3 are associated with ovarian cancer. BMC Womens Health. 2005 May 26;5:8. doi: 10.1186/1472-6874-5-8. PMID: 15918899; PMCID: PMC1175095.
Copy Download .nbib Format: NLM
Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers.

Genes & cancer

Peng M, Bakker JL, Dicioccio RA, Gille JJ, Zhao H, Odunsi K, Sucheston L, Jaafar L, Mivechi NF, Waisfisz Q, Ko L.
PMID: 23946868
Genes Cancer. 2013 Jan;4(1):15-25. doi: 10.1177/1947601913486344.

The human GT198 gene (gene symbol PSMC3IP) is located at chromosome 17q21, 470 kb proximal to BRCA1, a locus previously linked to breast and ovarian cancer predisposition. Its protein product (also known as TBPIP and Hop2) has been shown...

Cite
Peng M, Bakker JL, Dicioccio RA, et al. Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers. Genes Cancer. 2013;4(1):15-25doi: 10.1177/1947601913486344.
Peng, M., Bakker, J. L., Dicioccio, R. A., Gille, J. J., Zhao, H., Odunsi, K., Sucheston, L., Jaafar, L., Mivechi, N. F., Waisfisz, Q., & Ko, L. (2013). Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers. Genes & cancer, 4(1), 15-25. https://doi.org/10.1177/1947601913486344
Peng, Min, et al. "Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers." Genes & cancer vol. 4,1 (2013): 15-25. doi: https://doi.org/10.1177/1947601913486344
Peng M, Bakker JL, Dicioccio RA, Gille JJ, Zhao H, Odunsi K, Sucheston L, Jaafar L, Mivechi NF, Waisfisz Q, Ko L. Inactivating Mutations in GT198 in Familial and Early-Onset Breast and Ovarian Cancers. Genes Cancer. 2013 Jan;4(1):15-25. doi: 10.1177/1947601913486344. PMID: 23946868; PMCID: PMC3743154.
Copy Download .nbib Format: NLM
Ecological risk assessment of pesticide mixtures in the alluvial aquifers of central Italy: Toward more realistic scenarios for risk mitigation.

The Science of the total environment

Di Lorenzo T, Cifoni M, Fiasca B, Di Cioccio A, Galassi DMP.
PMID: 29981516
Sci Total Environ. 2018 Dec 10;644:161-172. doi: 10.1016/j.scitotenv.2018.06.345. Epub 2018 Jul 04.

In this study we used the data of an extensive pesticide monitoring survey that took place in 11 alluvial aquifers of central Italy from 2010 to 2015 to explore 4 different scenarios of risk. The Scenarios 1 and 2...

Cite
Di Lorenzo T, Cifoni M, Fiasca B, et al. Ecological risk assessment of pesticide mixtures in the alluvial aquifers of central Italy: Toward more realistic scenarios for risk mitigation. Sci Total Environ. 2018;644:161-172doi: 10.1016/j.scitotenv.2018.06.345.
Di Lorenzo, T., Cifoni, M., Fiasca, B., Di Cioccio, A., & Galassi, D. M. P. (2018). Ecological risk assessment of pesticide mixtures in the alluvial aquifers of central Italy: Toward more realistic scenarios for risk mitigation. The Science of the total environment, 644161-172. https://doi.org/10.1016/j.scitotenv.2018.06.345
Di Lorenzo, Tiziana, et al. "Ecological risk assessment of pesticide mixtures in the alluvial aquifers of central Italy: Toward more realistic scenarios for risk mitigation." The Science of the total environment vol. 644 (2018): 161-172. doi: https://doi.org/10.1016/j.scitotenv.2018.06.345
Di Lorenzo T, Cifoni M, Fiasca B, Di Cioccio A, Galassi DMP. Ecological risk assessment of pesticide mixtures in the alluvial aquifers of central Italy: Toward more realistic scenarios for risk mitigation. Sci Total Environ. 2018 Dec 10;644:161-172. doi: 10.1016/j.scitotenv.2018.06.345. Epub 2018 Jul 04. PMID: 29981516.
Copy Download .nbib Format: NLM
Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases.

BMJ open ophthalmology

Kaiser PK, Kodjikian L, Korobelnik JF, Winkler J, Torri A, Zeitz O, Vitti R, Ahlers C, Zimmermann T, Dicioccio AT, Höchel J.
PMID: 30997397
BMJ Open Ophthalmol. 2019 Mar 20;4(1):e000185. doi: 10.1136/bmjophth-2018-000185. eCollection 2019.

OBJECTIVE: Explore relationships between systemic exposure to intravitreal aflibercept injection (IAI) and systemic pharmacodynamic effects via post hoc analyses of clinical trials of IAI for neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DME).METHODS AND ANALYSIS: Adults from...

Cite
Kaiser PK, Kodjikian L, Korobelnik JF, et al. Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. BMJ Open Ophthalmol. 2019;4(1):e000185doi: 10.1136/bmjophth-2018-000185.
Kaiser, P. K., Kodjikian, L., Korobelnik, J. F., Winkler, J., Torri, A., Zeitz, O., Vitti, R., Ahlers, C., Zimmermann, T., Dicioccio, A. T., & Höchel, J. (2019). Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. BMJ open ophthalmology, 4(1), e000185. https://doi.org/10.1136/bmjophth-2018-000185
Kaiser, Peter K, et al. "Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases." BMJ open ophthalmology vol. 4,1 (2019): e000185. doi: https://doi.org/10.1136/bmjophth-2018-000185
Kaiser PK, Kodjikian L, Korobelnik JF, Winkler J, Torri A, Zeitz O, Vitti R, Ahlers C, Zimmermann T, Dicioccio AT, Höchel J. Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. BMJ Open Ophthalmol. 2019 Mar 20;4(1):e000185. doi: 10.1136/bmjophth-2018-000185. eCollection 2019. PMID: 30997397; PMCID: PMC6440611.
Copy Download .nbib Format: NLM
Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection.

medRxiv : the preprint server for health sciences

O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM.
PMID: 34159343
medRxiv. 2021 Jun 14; doi: 10.1101/2021.06.14.21258569.

BACKGROUND: Casirivimab and imdevimab administered together (REGEN-COV™) markedly reduces the risk of hospitalization or death in high-risk, symptomatic individuals with COVID-19. Here, we report phase 3 results of early treatment of asymptomatic, SARS-CoV-2-positive adults and adolescents with subcutaneous REGEN-COV.METHODS:...

Cite
O'Brien MP, Forleo-Neto E, Sarkar N, et al. Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. medRxiv. 2021;doi: 10.1101/2021.06.14.21258569.
O'Brien, M. P., Forleo-Neto, E., Sarkar, N., Isa, F., Hou, P., Chan, K. C., Musser, B. J., Bar, K. J., Barnabas, R. V., Barouch, D. H., Cohen, M. S., Hurt, C. B., Burwen, D. R., Marovich, M. A., Heirman, I., Davis, J. D., Turner, K. C., Ramesh, D., Mahmood, A., Hooper, A. T., Hamilton, J. D., Kim, Y., Purcell, L. A., Baum, A., Kyratsous, C. A., Krainson, J., Perez-Perez, R., Mohseni, R., Kowal, B., DiCioccio, A. T., Stahl, N., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G. D., & Weinreich, D. M. (2021). Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.06.14.21258569
O'Brien, Meagan P, et al. "Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.06.14.21258569
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM. Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. medRxiv. 2021 Jun 14; doi: 10.1101/2021.06.14.21258569. PMID: 34159343; PMCID: PMC8219113.
Copy Download .nbib Format: NLM
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19.

The New England journal of medicine

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD.
PMID: 34587383
N Engl J Med. 2021 Dec 02;385(23):e81. doi: 10.1056/NEJMoa2108163. Epub 2021 Sep 29.

BACKGROUND: In the phase 1-2 portion of an adaptive trial, REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of medical visits in patients with coronavirus disease 2019 (Covid-19). REGEN-COV has activity...

Cite
Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021;385(23):e81doi: 10.1056/NEJMoa2108163.
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Xiao, J., Hooper, A. T., Hamilton, J. D., Musser, B. J., Rofail, D., Hussein, M., Im, J., Atmodjo, D. Y., Perry, C., Pan, C., Mahmood, A., Hosain, R., Davis, J. D., Turner, K. C., Baum, A., Kyratsous, C. A., Kim, Y., Cook, A., Kampman, W., Roque-Guerrero, L., Acloque, G., Aazami, H., Cannon, K., Simón-Campos, J. A., Bocchini, J. A., Kowal, B., DiCioccio, A. T., Soo, Y., Geba, G. P., Stahl, N., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G. D. (2021). REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. The New England journal of medicine, 385(23), e81. https://doi.org/10.1056/NEJMoa2108163
Weinreich, David M, et al. "REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19." The New England journal of medicine vol. 385,23 (2021): e81. doi: https://doi.org/10.1056/NEJMoa2108163
Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021 Dec 02;385(23):e81. doi: 10.1056/NEJMoa2108163. Epub 2021 Sep 29. PMID: 34587383; PMCID: PMC8522800.
Copy Download .nbib Format: NLM
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.

medRxiv : the preprint server for health sciences

O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM.
PMID: 34159343
medRxiv. 2021 Sep 18; doi: 10.1101/2021.06.14.21258569.

IMPORTANCE: Easy-to-administer antiviral treatments may be used to prevent progression from asymptomatic infection to COVID-19 and to reduce viral carriage.OBJECTIVE: Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab antibody combination (REGEN-COV) to prevent progression from early asymptomatic...

Cite
O'Brien MP, Forleo-Neto E, Sarkar N, et al. Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. medRxiv. 2021;doi: 10.1101/2021.06.14.21258569.
O'Brien, M. P., Forleo-Neto, E., Sarkar, N., Isa, F., Hou, P., Chan, K. C., Musser, B. J., Bar, K. J., Barnabas, R. V., Barouch, D. H., Cohen, M. S., Hurt, C. B., Burwen, D. R., Marovich, M. A., Brown, E. R., Heirman, I., Davis, J. D., Turner, K. C., Ramesh, D., Mahmood, A., Hooper, A. T., Hamilton, J. D., Kim, Y., Purcell, L. A., Baum, A., Kyratsous, C. A., Krainson, J., Perez-Perez, R., Mohseni, R., Kowal, B., DiCioccio, A. T., Stahl, N., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G. D., Weinreich, D. M. (2021). Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.06.14.21258569
O'Brien, Meagan P, et al. "Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.06.14.21258569
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM. Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. medRxiv. 2021 Sep 18; doi: 10.1101/2021.06.14.21258569. PMID: 34159343; PMCID: PMC8219113.
Copy Download .nbib Format: NLM
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.

Journal of pharmacokinetics and pharmacodynamics

Yang F, Paccaly AJ, Rippley RK, Davis JD, DiCioccio AT.
PMID: 33728546
J Pharmacokinet Pharmacodyn. 2021 Aug;48(4):479-494. doi: 10.1007/s10928-021-09739-y. Epub 2021 Mar 16.

Cemiplimab, a human monoclonal antibody targeting programmed cell death-1 (PD-1) receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety profile comparable to other anti-PD-1 therapies. This population pharmacokinetics (PopPK) analysis of cemiplimab included 11,178 pharmacokinetics (PK)...

Cite
Yang F, Paccaly AJ, Rippley RK, et al. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. J Pharmacokinet Pharmacodyn. 2021;48(4):479-494doi: 10.1007/s10928-021-09739-y.
Yang, F., Paccaly, A. J., Rippley, R. K., Davis, J. D., & DiCioccio, A. T. (2021). Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. Journal of pharmacokinetics and pharmacodynamics, 48(4), 479-494. https://doi.org/10.1007/s10928-021-09739-y
Yang, Feng, et al. "Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies." Journal of pharmacokinetics and pharmacodynamics vol. 48,4 (2021): 479-494. doi: https://doi.org/10.1007/s10928-021-09739-y
Yang F, Paccaly AJ, Rippley RK, Davis JD, DiCioccio AT. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. J Pharmacokinet Pharmacodyn. 2021 Aug;48(4):479-494. doi: 10.1007/s10928-021-09739-y. Epub 2021 Mar 16. PMID: 33728546; PMCID: PMC8225544.
Copy Download .nbib Format: NLM
Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature Review.

Digital biomarkers

Perry B, Herrington W, Goldsack JC, Grandinetti CA, Vasisht KP, Landray MJ, Bataille L, DiCicco RA, Bradley C, Narayan A, Papadopoulos EJ, Sheth N, Skodacek K, Stem K, Strong TV, Walton MK, Corneli A.
PMID: 29938250
Digit Biomark. 2018 Jan 31;2(1):11-30. doi: 10.1159/000486347. eCollection 2018.

BACKGROUND: The use of mobile devices in clinical research has advanced substantially in recent years due to the rapid pace of technology development. With an overall aim of informing the future use of mobile devices in interventional clinical research...

Cite
Perry B, Herrington W, Goldsack JC, et al. Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature Review. Digit Biomark. 2018;2(1):11-30doi: 10.1159/000486347.
Perry, B., Herrington, W., Goldsack, J. C., Grandinetti, C. A., Vasisht, K. P., Landray, M. J., Bataille, L., DiCicco, R. A., Bradley, C., Narayan, A., Papadopoulos, E. J., Sheth, N., Skodacek, K., Stem, K., Strong, T. V., Walton, M. K., & Corneli, A. (2018). Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature Review. Digital biomarkers, 2(1), 11-30. https://doi.org/10.1159/000486347
Perry, Brian, et al. "Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature Review." Digital biomarkers vol. 2,1 (2018): 11-30. doi: https://doi.org/10.1159/000486347
Perry B, Herrington W, Goldsack JC, Grandinetti CA, Vasisht KP, Landray MJ, Bataille L, DiCicco RA, Bradley C, Narayan A, Papadopoulos EJ, Sheth N, Skodacek K, Stem K, Strong TV, Walton MK, Corneli A. Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature Review. Digit Biomark. 2018 Jan 31;2(1):11-30. doi: 10.1159/000486347. eCollection 2018. PMID: 29938250; PMCID: PMC6008882.
Copy Download .nbib Format: NLM
Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection.

medRxiv : the preprint server for health sciences

O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM.
PMID: 34159343
medRxiv. 2021 Jun 14; doi: 10.1101/2021.06.14.21258569.

BACKGROUND: Casirivimab and imdevimab administered together (REGEN-COV™) markedly reduces the risk of hospitalization or death in high-risk, symptomatic individuals with COVID-19. Here, we report phase 3 results of early treatment of asymptomatic, SARS-CoV-2-positive adults and adolescents with subcutaneous REGEN-COV.METHODS:...

Cite
O'Brien MP, Forleo-Neto E, Sarkar N, et al. Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. medRxiv. 2021;doi: 10.1101/2021.06.14.21258569.
O'Brien, M. P., Forleo-Neto, E., Sarkar, N., Isa, F., Hou, P., Chan, K. C., Musser, B. J., Bar, K. J., Barnabas, R. V., Barouch, D. H., Cohen, M. S., Hurt, C. B., Burwen, D. R., Marovich, M. A., Heirman, I., Davis, J. D., Turner, K. C., Ramesh, D., Mahmood, A., Hooper, A. T., Hamilton, J. D., Kim, Y., Purcell, L. A., Baum, A., Kyratsous, C. A., Krainson, J., Perez-Perez, R., Mohseni, R., Kowal, B., DiCioccio, A. T., Stahl, N., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G. D., & Weinreich, D. M. (2021). Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.06.14.21258569
O'Brien, Meagan P, et al. "Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.06.14.21258569
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM. Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. medRxiv. 2021 Jun 14; doi: 10.1101/2021.06.14.21258569. PMID: 34159343; PMCID: PMC8219113.
Copy Download .nbib Format: NLM
Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.

Journal of clinical pharmacology

Paccaly AJ, Kovalenko P, Parrino J, Boyapati A, Xu C, van Hoogstraten H, Ishii T, Davis JD, DiCioccio AT.
PMID: 32726514
J Clin Pharmacol. 2021 Jan;61(1):90-104. doi: 10.1002/jcph.1703. Epub 2020 Jul 29.

We assessed pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships of interleukin-6 (IL-6), soluble IL-6 receptor, and C-reactive protein (CRP) in serum, and absolute neutrophil count (ANC) in blood following single doses of subcutaneous sarilumab versus intravenous tocilizumab (NCT02097524) from...

Cite
Paccaly AJ, Kovalenko P, Parrino J, et al. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. J Clin Pharmacol. 2020;61(1):90-104doi: 10.1002/jcph.1703.
Paccaly, A. J., Kovalenko, P., Parrino, J., Boyapati, A., Xu, C., van Hoogstraten, H., Ishii, T., Davis, J. D., & DiCioccio, A. T. (2021). Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. Journal of clinical pharmacology, 61(1), 90-104. https://doi.org/10.1002/jcph.1703
Paccaly, Anne J, et al. "Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate." Journal of clinical pharmacology vol. 61,1 (2021): 90-104. doi: https://doi.org/10.1002/jcph.1703
Paccaly AJ, Kovalenko P, Parrino J, Boyapati A, Xu C, van Hoogstraten H, Ishii T, Davis JD, DiCioccio AT. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. J Clin Pharmacol. 2021 Jan;61(1):90-104. doi: 10.1002/jcph.1703. Epub 2020 Jul 29. PMID: 32726514; PMCID: PMC7754484.
Copy Download .nbib Format: NLM
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.

JAMA

O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM.
PMID: 35029629
JAMA. 2022 Jan 14; doi: 10.1001/jama.2021.24939. Epub 2022 Jan 14.

IMPORTANCE: Easy-to-administer anti-SARS-CoV-2 treatments may be used to prevent progression from asymptomatic infection to symptomatic disease and to reduce viral carriage.OBJECTIVE: To evaluate the effect of combination subcutaneous casirivimab and imdevimab on progression from early asymptomatic SARS-CoV-2 infection to...

Cite
O'Brien MP, Forleo-Neto E, Sarkar N, et al. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2022;doi: 10.1001/jama.2021.24939.
O'Brien, M. P., Forleo-Neto, E., Sarkar, N., Isa, F., Hou, P., Chan, K. C., Musser, B. J., Bar, K. J., Barnabas, R. V., Barouch, D. H., Cohen, M. S., Hurt, C. B., Burwen, D. R., Marovich, M. A., Brown, E. R., Heirman, I., Davis, J. D., Turner, K. C., Ramesh, D., Mahmood, A., Hooper, A. T., Hamilton, J. D., Kim, Y., Purcell, L. A., Baum, A., Kyratsous, C. A., Krainson, J., Perez-Perez, R., Mohseni, R., Kowal, B., DiCioccio, A. T., Geba, G. P., Stahl, N., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G. D., Weinreich, D. M. (2022). Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA, . https://doi.org/10.1001/jama.2021.24939
O'Brien, Meagan P, et al. "Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial." JAMA vol. (2022). doi: https://doi.org/10.1001/jama.2021.24939
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2022 Jan 14; doi: 10.1001/jama.2021.24939. Epub 2022 Jan 14. PMID: 35029629.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries